Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
Oncology advanced practice providers should have comprehensive knowledge and competency in the area of survivorship care. This module explores the considerations and principles of comprehensive survival care of the patient with cancer.
The Oncology Nursing Society has compiled a library of a variety of resources to help inform nurses about hematologic malignancies and conditions, cellular therapies, and stem cell transplantations.
The use of oral anticancer medications continues to expand. Oncology nurses and their colleagues can benefit from a growing number of resources created to support patients taking these therapies.
Cabozantinib (Cabometyx®) received an additional U.S. Food and Drug Administration (FDA)-approved indication in January 2019 for use in patients with hepatocellular carcinoma (HCC) who have already been treated with sorafenib. It received prior approval for the treatment of renal cell carcinoma in 2017. The research leading to the approval in the HCC setting showed improved overall survival, progression-free survival, and overall response in the cabozantinib treatment arm.
This module explores unique professional issues that accompany advanced oncology nursing practice. Explore topics including APRN education, accreditation, licensure, and certification standards, as well as professional roles and state practice acts.
Serving on a board of directors is an effective way to engage and implement the change that you’d like to see in your practice. Use your experience to shape the future for oncology nurses and patient care either through ONS or at any number of healthcare
This module explores the considerations and principles of comprehensive survivorship care of patients with cancer. Learn considerations of each treatment modality, psychosocial and spiritual impacts of treatment, best practice, and the essential influence of the advanced practice provider in care of the cancer survivor.
After clinical trial results demonstrated a four-month improvement in overall survival compared to best standard care, in March 2022 the U.S. Food and Drug Administration approved lutetium lu 177 vipivotide tetraxetan (PluvictoTM) to treat prostate-specific membrane antigen (PSMA)–expressing metastatic castration-resistant prostate cancer (mCRPC).